Q192R paraoxonase gene 1 (PON1) polymorphism and atorvastatin therapy effect in patients with type 2 diabetes mellitus (T2DM)

Study objective: to estimate efficiency of atorvastatin therapy in patients with type 2 diabetes mellitus (T2DM), who are the carrier of various genotypes Q192R paraoxonase gene 1 (PON1). 386 T2DM patients, who have not received statin therapy before, and 187 healthy people were examined. All those examined were exposed to blood lipid profile testing and molecular genetic research. The atorvastatin treatment group included 164 T2DM patients with abnormality of lipids, their blood lipid profile values were assessed before and after 3 months of the therapy. Blood lipid profile values did not differ in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism. Atorvastatin therapy decreased atherogenic lipoprotein levels in type 2 diabetes mellitus patients (T2DM) - the carriers of different Q192R genotypes of paraoxonase gene 1 (PON1) polymorphism, but reduction degree in the carriers of different Q192R genotypes differed - in Q192Q bearers it was greater than in the bearers of Q192R genotype of gene PON1 (р = 0,031). Atorvastatin 3-months therapy revealed greater reduction of total cholesterol in the carriers of Q192Q genotype of gene 1 (PON1) than in the carriers of Q192R genotype of gene 1 (PON1).

сахарный диабет, дислипидемия, ген параоксоназы 1, аторвастатин, diabetes mellitus, dyslipidemia, paraoxonase 1 gene, atorvastatin

1. Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Вып. 7 // Сахарный диабет. - 2015. - Спец. вып. 1. - С. 1-112.

2. American Diabetes Association. Standards of medical care in diabetes // Diabetes Care. - 2015. - Vol. 38. - P. 1-93.

3. Abdin A. A. et al. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy // J. Diabetes Complications. - 2010. - Vol. 24. - P. 325 - 333.

4. Altuner D., Ates I., Suzen S. H. et al. The relationship of PON1 QR192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients // ToxicolInd Health. - 2011. - Vol. 27 (10). - P. 873 - 878.

5. Christidis D. S., Liberopoulos E. N., Kakafika A. I. et al. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin // Arch. Med. Res. - 2007. - Vol. 38. - P. 403-410.

6. Fu R., Sun Y., Su Y. et al. Effect of statins therapy on plazma high-density lipoprotein-cholesterol levels is modified by pa-raoxonase 1 in Chinese patients with coronary heart disease // Clinical and Experimental Pharmacology and Physiology. - 2008. - P. 982 - 983.

7. Gokcen S., Cengiz M., Ozaydin A. Serum Paraoxonase Levels and PON1(192) Polymorphism in Type 2 Diabetes Mellitus Patients // GMJ. - 2013. - Vol. 24. - P. 70 - 73.

8. Mirdamadi H. Z., Sztanek F., Derdak Z. et al. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters // Br. J. Clin. Pharmacol. - 2008. - Vol. 66. - P. 366 - 374.

9. Turban S., Fuentes F., Ferlic L. et al. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin // Atherosclerosis. - 2001. - Vol. 154. - P. 633 - 640.